Compare CENN & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | CURX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 9.4M |
| IPO Year | 2017 | 2025 |
| Metric | CENN | CURX |
|---|---|---|
| Price | $3.27 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 61.8K |
| Earning Date | 04-15-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,080,161.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $0.21 |
| 52 Week High | $4.73 | $9.18 |
| Indicator | CENN | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 30.90 |
| Support Level | $0.14 | N/A |
| Resistance Level | $4.50 | $0.40 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 20.97 | 7.43 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, iChassis, Avantier, Teemak, Bison Motor, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the Europe, and also has a presence in America, Asia, and other regions.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.